Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Point-of-Care Diagnostics & Biosensors Europe 2018

Richard Spero's Biography



Richard Spero, CEO, Redbud Labs

Richard Spero is co-founder and CEO of Redbud Labs, where he leads both commercial activities and the company’s systems engineering team. He is a co-inventor of Redbud Posts, a MEMS chip covered with biomimetic cilia. Redbud Posts enable novel methods for fluid processing at the microscale, including pumping, mixing, cell sorting, and analyte isolation. This technology is used by point-of-care diagnostic device developers to improve assay speed, reliability, and performance. Prior to founding Redbud Labs, Dr. Spero earned his PhD in Physics at the University of North Carolina at Chapel Hill, where he studied blood clot rheology and developed novel systems for magnetic manipulation and time-dependent high content screening.

Richard Spero Image

Conference Chairman Welcome and Opening Remarks

Tuesday, 5 June 2018 at 08:15

Add to Calendar ▼2018-06-06 09:30:002018-06-06 10:30:00Europe/LondonMaking Molecular Diagnostics More Sensitive, Cheaper with Microfluidic MixingPoint-of-Care Diagnostics and Biosensors Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Making Molecular Diagnostics More Sensitive, Cheaper with Microfluidic Mixing

Wednesday, 6 June 2018 at 09:30

Add to Calendar ▼2018-06-06 09:30:002018-06-06 10:30:00Europe/LondonMaking Molecular Diagnostics More Sensitive, Cheaper with Microfluidic MixingPoint-of-Care Diagnostics and Biosensors Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Molecular diagnostics are rapidly moving from the central lab to point-of-care. Several new rapid, compact platforms are coming on the market, but poor limit of detection (LOD) limits their clinical utility. We report on recent case studies where our microfluidic mixing chip, MXR, was added to existing systems to dramatically accelerate molecular assays, improving LOD by up to 100x and enabling detection at single-digit copy number. Surprisingly, MXR did not increase cartridge cost. To the contrary, a design revision reduced cartridge cost by 2x.


Add to Calendar ▼2018-06-05 00:00:002018-06-06 00:00:00Europe/LondonPoint-of-Care Diagnostics and Biosensors Europe 2018Point-of-Care Diagnostics and Biosensors Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com